Ophthalmology

Intravitreal anti-VEGF injections were associated with an increase in the likelihood of systemic adverse events among patients with diabetic retinopathy.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our May 2023 month-in-review features new FDA approvals, the future of artificial intelligence in eye care, and interesting crossover coverage.

The findings could provide insight into incorporating both OCTA and artificial intelligence for early detection of DMI and better enhancing the management of diabetic retinopathy.

However, trends in the incidence of eye injuries associated with non-powder guns should be interpreted with caution as COVID-19 may have interfered with epidemiological trends.

Announced by Bausch + Lomb and Novaliq, the prescription eye drop for DED is the first and only drop that directly targets tear evaporation, with approval based on results from 2 pivotal phase 3 trials.

Cost-effective smartphone-based fundus imaging systems may be effective for the detection of treatment-requiring ROP, and help increase the global capacity for ROP screening.

A recent analysis suggests that incorporating retinal and choroidal microvascular metrics may improve the identification of eyes with no diabetic retinopathy from those with DR.

A lack of a significant refractive error and visiting an optometrist rather than an ophthalmologist were factors associated with a missed diagnosis of primary open-angle glaucoma, according to a recent analysis.

The use of other antihypertensive medications, lipid-lowering medications, antidepressants, or antidiabetic medications were not clearly associated with glaucoma in a recent analysis.

An analysis of real-life data indicates the role of adalimumab in reducing the frequency and/or severity of ocular flares in pediatric patients with non-infectious non-anterior uveitis.

A prospective study on patients with DR and CKD found no significant effect on renal function shortly after performing fluorescein angiography.

Results suggest patients with age-related macular degeneration who have visual disability should be targets for risk factor management and disease prevention for cardiovascular disease.

An AI-based fundus screening system used in a real-world setting was able to distinguish between normal and abnormal ocular fundus and diagnose 5 prevalent ocular conditions.

Logistic regression analysis indicated that higher stages of urine albumin creatine ratio were significantly associated with diabetic retinopathy in patients with T2D and diabetic nephropathy.

The findings of a recent diagnostic study suggest that AI was able to infer the self-reported race of infants from retinal vessel maps, something human graders are unable to do.

A new study suggests ChatGPT may not provide substantial assistance in preparing for board certification at this time.

Pending FDA approval, RVO would be the third indication for faricimab-svoa in addition to wet age-related macular degeneration and diabetic macular edema.

The approval, granted to Eyenovia, Inc, represents the first-approved fixed-dose combination of tropicamide and phenylephrine for inducing mydriasis for diagnostic procedures and short-term pupil dilation.

Intravitreal steroid treatment for DME was associated with no significant differences in BCVA, but a higher risk of IOP-related events, compared to anti-VEGF therapy.

At ARVO 2023, Schmidt-Erfurth discusses new insights regarding disease activity in GA, observing reductions in both RPE and photoreceptor degeneration after intravitreal pegcetacoplan therapy in the OAKS and DERBY trials.

At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.

At ARVO 2023, Elizabeth Rossin, MD, PhD, elaborates on genetic and biological pathways that may contribute to epiretinal membrane risk.

A retrospective study of nearly 19,000 eyes presented at ARVO 2023 found patients with GA lost 2 lines of vision at year 3 and are at meaningful risk of nAMD.

At ARVO 2023, David Tabano, PhD, discussed the analysis of the largest real-world evaluation of treatment patterns and outcomes in DME patients treated with faricimab.

At ARVO 2023, Goldberg discusses how dual Ang-2/VEGF inhibition can provide greater vascular stability, which may contribute to faster fluid resolution and extended durability with faricimab treatment.

A personalized treat-and-extend–based regimen presented at ARVO 2023 suggested the long-term potential of faricimab to reduce the treatment burden for patients with DME.

Brandon Ayres, MD, provides an overview of lifitegrast efficacy and safety from the OPUS trials for the treatment of dry eye disease.

Laura Periman, MD, describes the mechanism of action of lifitegrast for the treatment of dry eye disease.

An analysis of the phase 2/3 PHOTON trial suggested the majority of patients with DME who received aflibercept 8 mg maintained 12- or 16-week dosing intervals.

At ARVO 2023, Do discusses the benefit of aflibercept 8 mg for DME in the phase 2/3 PHOTON trial, demonstrating non-inferiority in BCVA vs aflibercept 2 mg and no new safety concerns.